BioSpace News Archive

MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced that it has completed management changes to enhance its focus on its dermatological services and products (“DSP”) including DermSecure™ and SIAscopy™. Mike Druhan, who has championed SIAscopy™ within the Company for a number of years, has been appointed President, Dermatological Services and Products. The supporting teams in sales, training, pro

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today updated timelines indicating 3-6 months delay for the planned Phase Ib study with ATOR-1015, its tumor-localizing, bispecific CTLA-4 and OX40 antibody developed for treatment of metastatic cancer. As previously communicated, preliminary data from the ongoing Phase

Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing urokinase plasminogen activator receptor targeted radio-immuno-therapeutics (uPRITs) for the potential treatment of patients with severe COVID-19, today announced a collaboration with The University of Texas Health Science Center at Tyler (UTHSCT) and its Texas Lung Injury Institute (TLII)

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference at 3:30 p.m. ET on Tuesday, September 15, 2020. Company management will also participate in one-on-one mee

Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer and John Gandolfo, Eyenovia’s Chief Financial Officer, are scheduled to present at the 22 nd Annual H.C. Wainwright Global Investment Conference being held virtually on September 14-16, 2020. Deta

PDL BioPharma, Inc. (“PDL” or the “Company”) (Nasdaq: PDLI) announces the closing of the sale of its wholly owned subsidiaries Noden Pharma DAC and Noden Pharma USA (collectively “Noden”) to Stanley Capital. The total value of the transaction will result in payments to PDL of up to $52.83 million in cash, $4.58 milli

A new in vitro study just published in the Journal of Gastroenterology Research by Howard F. Robins and A. Reza Kamarei has shown complete inhibition of Clostridium difficile (C. diff) , a life-threatening diarrhea causing bacteria, by a patent-pending synbiotic product (blend of 15 strains of living probiotics in a blend of organic vegetable-fruit juice)

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the limited availability of the new Precice® Plate for use in limb lengthening and reconstruction procedures from NuVasive Specialized Orthopedics

Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of S. Gail Eckhardt, M.D., to the Company’s Board of Directors. Dr. Eckhardt is a highly respected oncologist and a leader in targeted oncology drug development. “Gail brings tremendous vision and experience in translational and clinical research, with a focus on combi

IntrinsiQ Specialty Solutions, a part of AmerisourceBergen, today announced the launch of UroChartEHR Telehealth, a new HIPAA-compliant, virtual visit tool created in partnership with Backline by DrFirst.